Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025

Amgen (AMGN) recently declared a $2.38 dividend per share, continuing its practice of rewarding shareholders, which aligns with a 5.6% price increase over the last quarter. During this period, Amgen announced successful Phase 3 clinical trial results, potentially boosting investor confidence. Additionally, amidst broader market volatility influenced by weak job reports and tariff concerns, Amgen's strong clinical outcomes and dividend declaration might have cushioned its stock against broader declines. While the general market faced a 2.7% drop recently, Amgen’s secure dividend and promising product pipeline offered a stabilizing counterweight.

We've identified 1 risk with Amgen and understanding the impact should be part of your investment process.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 25 best rare earth metal stocks of the very few that mine this essential strategic resource.

The recent developments surrounding Amgen, including the dividend declaration and successful Phase 3 clinical trial results, potentially bolster investor confidence, despite concurrent macroeconomic challenges. Over the past five years, Amgen's total returns, including share price appreciation and dividends, stood at 44.13%, illustrating a robust performance against the backdrop of evolving industry dynamics. In the last year, the company underperformed the broader US Biotechs industry, which saw an 8.4% return decline. This demonstrates Amgen's resilience amid wider market trends, coupled with sustained returns over a longer term.

The successful clinical trial outcomes have the potential to positively influence revenue and earnings forecasts, mitigating concerns associated with pricing pressures and biosimilar competition. These developments could support a stabilization or growth in revenue streams contrary to the bearish outlook outlined in the narrative. Additionally, Amgen's current share price of US$296.88 presents a slight discount to the consensus analyst price target of US$313.48, suggesting that market expectations align closely with Amgen's medium-term benchmarks. This price variance, alongside the company's strategic product advancements, indicates optimistic valuation prospects in the eyes of investors and analysts alike.

Assess Amgen's future earnings estimates with our detailed growth reports.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.